Meeting
2019 Gastrointestinal Cancers Symposium
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.
Authors
Thomas J. George
NSABP Foundation, and The University of Florida, Gainesville, FL
Thomas J. George , Greg Yothers , James J. Lee , Samuel A. Jacobs , Melvin Deutsch , Carmen Joseph Allegra , Norman Wolmark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT03102047
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr TPS727)
DOI
10.1200/JCO.2019.37.4_suppl.TPS727
Abstract #
TPS727
Poster Bd #
Q12
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.
First Author: Thomas J. George
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.
First Author: Thomas J. George
Poster
2018 ASCO Annual Meeting
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer.
First Author: Thomas J. George Jr.
Poster
2020 ASCO Virtual Scientific Program
Phase II study of durvalumab plus total neoadjuvant therapy (TNT) in locally advanced rectal cancer: The GEMCAD-1703 DUREC trial.
First Author: Jaume Capdevila